Key Takeaway: The article discusses a pediatric sub-study focusing on the safety of Arimoclomol for Niemann-pick Disease Type C patients aged 6 to less than 24 months. This study is set to be presented at the 21st Annual WORLDSymposium on February 5, 2025. The research aims to provide insights into the treatment's safety profile in a vulnerable population.
Price reaction · baseline $7.84 (2025-01-31 close) · hit pre-market · 4 other ZVRA headline(s) in the window, move may be shared
day 0 close · peak
-2.4%
Market Sentiment Analysis
POSITIVE FACTORS
Focus on safety of Arimoclomol in young patients.
Study targets a specific age group with Niemann-pick Disease Type C.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Medical Publications and Presentations
Safety of Arimoclomol in a Pediatric Sub-Study of Niemann-pick Disease Type C Patients Aged 6 To <24 Months at Study Enrollment
21st Annual WORLDSymposium - 02/05/2025
Download PDF
Download PDF
Frequently Asked Questions
What is the focus of the Arimoclomol study?
The study focuses on the safety of Arimoclomol in pediatric patients with Niemann-pick Disease Type C.
What age group is involved in the study?
The study involves patients aged 6 to less than 24 months.
When will the study be presented?
The study will be presented at the 21st Annual WORLDSymposium on February 5, 2025.
What disease is being studied in relation to Arimoclomol?
The study is related to Niemann-pick Disease Type C.